

Biologic Medicines in Dermatology

Reference Number: RDF2224-24 Date of Response: 23/01/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Answer: Please see the table below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

Drug	No. of patients treated
Adalimumab - Humira	≤5
Adalimumab Biosimilar	207
Apremilast	10
Bimekizumab	≤5
Brodalumab	9
Certolizumab	11
Deucravacitinib	Nil
Dimethyl fumarate	≤5
Etanercept - Enbrel	Nil
Etanercept Biosimilar	≤5
Guselkumab	33
Infliximab - Remicade	Nil
Infliximab Biosimilar	Nil
Ixekizumab	39
Risankizumab	54
Secukinumab	66
Tildrakizumab	22
Ustekinumab	58

Q2. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:

Drug	No. of patients treated
Ciclosporin	Nil
Methotrexate - any form and strength	68
Methotrexate injections 15mg and above	43